Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern - Synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives

European Journal of Medicinal Chemistry

Volumn 38, Issue 1, 2003, Pages 101-107

  He, Ling ^a   Chang, He Xi ^b   Chou, Ting Chao ^c   Savaraj, Niramol ^d   Cheng, C C ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

11H Indolo 3.2 c quinoline derivatives; 2 Phenylnaphthalene type; Antitumor activity

Indexed keywords

2 PHENYLNAPHTHALENE; ANTINEOPLASTIC AGENT; NAPHTHALENE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CENTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG SMALL CELL CANCER; MOLECULE; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; INDOLES; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NAPHTHALENES; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037368393     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(02)01420-4     Document Type: Article

References (20)

1. Cheng C.C., Liu D.F., Chou T.C. Heterocycles. 35:1993;775-789.
2. Cheng C.C., Dong Q., Liu D.F., Luo Y.L., Liu L.F., Chen A.Y., Yu C., Savaraj N., Chou T.C. J. Med. Chem. 36:1993;4108-4112.
3. Luo Y.L., Chou T.C., Cheng C.C. J. Heterocycl. Chem. 33:1996;113-117.
4. Cheng C.C. Medical Hypotheses. 20:1986;157-172.
5. Cheng C.C., Ellis G.P., West G.B. Progress in Medicinal Chemistry. 25:1988;35-83 Elsevier Science Publishers, B.V. (Biomedical Division), Amsterdam.
6. Marquez V.E., Cranston J.W., Ruddon R.W., Kier L.B., Bukckhalter J.H. J. Med. Chem. 15:1972;36-39.
7. Riou J.F., Helissey P., Grondard L., Giorgi-Renault S. Molecular Pharmacol. 40:1991;699-706.
8. Elderfield R.C., Gensler W.J., Bembry T.H., Kremer C.B., Brody F., Hageman H.A., Head J.D. J. Am. Chem. Soc. 68:1946;1259-1263.
9. Elderfield R.C., Maggiolo A. J. Am. Chem. Soc. 71:1949;1906-1911.
10. Johnson W.S., Woroch E.L., Buell B.G. J. Am. Chem. Soc. 71:1949;1901-1905.
11. Koo J. J. Org. Chem. 28:1963;1134-1135.
12. Akermark B., Eberson L., Jonsson E., Pettersson E. J. Org. Chem. 40:1975;1365-1367. and references cited therein.
13. Bittner S., Krief P., Massil T. Synthesis. 1991;215-216.
14. Boyd M.R. Princ. Pract. Oncol. 3:1989;1-12.
15. Cain B.F., Atwell G.J., Denny W.A. J. Med. Chem. 18:1975;1110-1117.
16. Hamana M., Funakoshi K. Yakugaku Zasshi. 84:1964;42-47.
17. Denny W.A., Atwell G.J., Baguley B.C. Anti-Cancer Drug Des. 2:1997;263-270.
18. Clemo G.R., Perkin W.H. Jr. J. Chem. Soc. 125:1924;1608-1622.
19. Werbel L.M., Kesten S.J., Turner W.R. Eur. J. Med. Chem. 28:1993;837.
20. Roussel O., Buu-Hol N.P., Jacquignon P. J. Chem. Soc. 1965;5458.